Article
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.
Haematologica - 1 Sept 2016
Al-Ali Haifa Kathrin, Griesshammer Martin, le Coutre Philipp, Waller Cornelius F, Liberati Anna Marina, Schafhausen Philippe, Tavares Renato, Giraldo Pilar, Foltz Lynda, Raanani Pia, Gupta Vikas, Tannir Bayane, Ronco Julian Perez, Ghosh Jagannath, Martino Bruno, Vannucchi Alessandro M
Abstract excerpt
JUMP is a phase 3b expanded-access trial for patients without access to ruxolitinib outside of a clinical study; it is the largest clinical trial to date in patients with myelofibrosis who have been treated with ruxolitinib. Here, we present safety and efficacy findings from an analysis of 1144 patients with intermediate- or high-risk myelofibrosis, as well as a separate analysis of 163 patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.